Drug Trial Radar · NCT04505774
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
Last checked: Nov 20, 2026Latest source record: Dec 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,591
Actual
Start
Sep 4, 2020
Primary completion
Aug 31, 2023
Study completion Jan 26, 2024
Sponsor
- Lead sponsor
- Matthew Neal MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Aug 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic and additional strategies for prevention of adverse outcomes in COVID-19 positive inpatients
Conditions
- Covid19
Interventions
theraputic heparinDrug
increased dose of heparin above standard of care.
prophylactic heparinDrug
standard of care dose of heparin
P2Y12Drug
added P2Y12 inhibitor
Crizanlizumab InjectionDrug
crizanlizumab injection
SGLT2 inhibitorDrug
sglt2 inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- 21 Day Organ Support (Respiratory or Vasopressor) Free DaysTime frame: 21 days from study enrollment
Locations
101 sites in 4 countries. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama
University of Arizona
Tucson, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Kaiser Permanente Fontana
Fontana, California
Kaiser Permanente Los Angeles
Los Angeles, California
Smidt Heart Institute at Cedars-Sinai
Los Angeles, California
Ronald Reagan UCLA Medical Center
Los Angeles, California
UC San Diego Hillcrest
San Diego, California
Zuckerberg San Francisco General Hospital
San Francisco, California
UCSF San Francisco
San Francisco, California
Zuckerberg San Francisco General Hospital
San Francisco, California
Stanford University Medical Center
Stanford, California
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California
Denver Health and Hospital Authority
Denver, Colorado
St. Mary's Hospital & Regional Medical Center
Grand Junction, Colorado
Saint Francis Hospital and Medical Center
Hartford, Connecticut
University of Florida
Gainesville, Florida
Memorial Hospital
Jacksonville, Florida
AdventHealth Tampa
Tampa, Florida
Emory
Atlanta, Georgia
Morehouse School of Medicine
Atlanta, Georgia
Queens Medical Center
Honolulu, Hawaii
Memorial Hospital
Belleville, Illinois
Cook County Health
Chicago, Illinois
University of Illinois at Chicago Health (UIH)
Chicago, Illinois
OSF Little Company of Mary Medical Center (OSF LCM)
Evergreen Park, Illinois
Indiana University Health Methodist Hospital
Indianapolis, Iowa
Kansas University Medical Center
Kansas City, Kansas
Ochsner Clinic Foundation
New Orleans, Louisiana
Boston University
Boston, Massachusetts
St Elizabeth's Medical Center
Brighton, Massachusetts
Baystate Medical Center
Springfield, Massachusetts
University of Massachusetts
Worcester, Massachusetts
University of Michigan
Ann Arbor, Michigan
Wayne State University
Detroit, Michigan
Hennepin County Medical Center
Minneapolis, Minnesota
University of Mississippi Medical Center
Jackson, Mississippi
Washington University School of Medicine, ACCS Research
St Louis, Missouri
University Medical Center of Southern Nevada
Las Vegas, Nevada
Cooper Health
Camden, New Jersey
Showing 40 of 101 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.